{"id":15438,"date":"2023-11-30T10:00:39","date_gmt":"2023-11-30T09:00:39","guid":{"rendered":"https:\/\/www.bm-t.de\/?p=15438"},"modified":"2023-11-30T10:05:50","modified_gmt":"2023-11-30T09:05:50","slug":"bmt-sells-its-shares-in-bianogmp-to-euroapi","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2023-en\/bmt-sells-its-shares-in-bianogmp-to-euroapi\/","title":{"rendered":"bm|t sells its shares in BianoGMP GmbH to EUROAPI"},"content":{"rendered":"

EUROAPI<\/a>, a lead\u00ading provider of small mol\u00ade\u00adcule APIs and listed on Euronext Paris, has acquired 100% of the shares in BianoGMP GmbH<\/a> (\u201cBianoGMP\u201d).<\/p>\n

BianoGMP, based in Gera (Thuringia), was founded in 2017 by Prof. Dr. Tobias P\u00f6hlmann and Dr. Rolf G\u00fcn\u00adther and is an oligonu\u00adcleotide Con\u00adtract Devel\u00adop\u00adment and Man\u00adu\u00adfac\u00adtur\u00ading Orga\u00adni\u00adza\u00adtion (CDMO) player focused on small-scale, early-stage (pre-clin\u00adi\u00adcal to phase 1), com\u00adplex and cus\u00adtomized projects, with a diver\u00adsi\u00adfied client base in Europe and Asia.<\/p>\n

With this acqui\u00adsi\u00adtion, EUROAPI aims to fur\u00adther strengthen its CDMO mar\u00adket posi\u00adtion in the oligonu\u00adcleotides sec\u00adtor. This trans\u00adac\u00adtion not only opens up oppor\u00adtu\u00adni\u00adties for cross-refer\u00adral com\u00admer\u00adcial syn\u00ader\u00adgies and sci\u00aden\u00adtific coop\u00ader\u00ada\u00adtion, but will also fur\u00adther dif\u00adfer\u00aden\u00adti\u00adate the value propo\u00adsi\u00adtion of EUROAPI to accom\u00adpany a wider client base across the whole oligonu\u00adcleotide devel\u00adop\u00adment con\u00adtin\u00aduum, from research to commercialization.<\/p>\n

Con\u00adsis\u00adtent with EUROAPI\u2019s entre\u00adpre\u00adneur\u00adial approach, BianoGMP will retain its cor\u00adpo\u00adrate brand and become a EUROAPI company.<\/p>\n

\u201cI am thrilled to have the oppor\u00adtu\u00adnity to con\u00adtinue to expand BianoGMP\u2019s capa\u00adbil\u00adi\u00adties in order to grow with our cus\u00adtomers and pro\u00advide GMP-batches also for later clin\u00adi\u00adcal phases,\u201d said Prof. Dr. Tobias P\u00f6hlmann. \u201cBianoGMP has a track record of hands-on sup\u00adport for inno\u00adv\u00ada\u00adtive oligonu\u00adcleotide devel\u00adop\u00adments, com\u00adplex chemistries and con\u00adju\u00adga\u00adtion of pep\u00adtides and lipids. With a client base in Europe and Asia, it will ben\u00ade\u00adfit from EUROAPI\u2019s sales and mar\u00adket\u00ading teams to expand into new geographies.\u201d<\/p>\n

\u201cWe at bm|t are proud to have sup\u00adported and accom\u00adpa\u00adnied BianoGMP in the process of set\u00adting up a GMP pro\u00adduc\u00adtion from the very begin\u00adning, together with a num\u00adber of co-investors,\u201d said Ste\u00adfan Jahn, Senior Invest\u00adment Man\u00adager at bm|t. \u201cWe are delighted that BianoGMP has found a strate\u00adgic part\u00adner and new owner in EUROAPI, who also wants to invest in the Gera loca\u00adtion and expand BianoGM\u00adP\u2019s pro\u00adduc\u00adtion capacities\u201d.<\/p>\n

More infor\u00adma\u00adtion about EUROAPI<\/strong><\/p>\n

https:\/www.euroapi.com\/<\/a><\/p>\n

More infor\u00adma\u00adtion about BianoGMP<\/strong><\/p>\n

https:\/\/www.bianogmp.com\/<\/a><\/p>\n

More infor\u00adma\u00adtion about bm|t<\/strong><\/p>\n

https:\/\/www.bm\u2011t.de\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

EUROAPI, a lead\u00ading provider of small mol\u00ade\u00adcule APIs, has acquired 100% of the shares in BianoGMP GmbH. BianoGMP is an oligonu\u00adcleotide Con\u00adtract Devel\u00adop\u00adment and Man\u00adu\u00adfac\u00adtur\u00ading Orga\u00adni\u00adza\u00adtion (CDMO) player focused on small-scale, early-stage (pre-clin\u00adi\u00adcal to phase 1), com\u00adplex and cus\u00adtomized projects, with a diver\u00adsi\u00adfied client base in Europe and Asia. <\/p>\n","protected":false},"author":2,"featured_media":5393,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[234],"tags":[157,210,159,171],"class_list":["post-15438","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2023-en","tag-exit-en","tag-investeepartner","tag-investment-en","tag-thuringia"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/15438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=15438"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/15438\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/5393"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=15438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=15438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=15438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}